FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
This article was originally published in The Rose Sheet
FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.
You may also be interested in...
FDA should not use size alone to regulate nanotechnology, the Consumer Healthcare Products Association says.
FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement
Gabriel Letizia Jr. potentially faces up to seven years in prison after admitting to defrauding AMA Laboratories customers of more than $46m by sending them bogus testing reports. The US FDA, which participated in the investigation, has not commented publicly on the implications for improperly tested sunscreens and other products.